LONDON--(BUSINESS WIRE)--Technavio has announced its latest pipeline analysis report on the acute coronary syndrome market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat acute coronary syndrome.
This report presents an in-depth analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and vendor landscape that are expected to play an essential role in the growth of the market during the forecast period.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Acute coronary syndrome - market overview
Acute coronary syndrome (ACS) affects the functioning of the heart because of the insufficient supply of blood in the coronary arteries. Atherosclerosis is the major cause of ACS. It is caused because of the build-up plaque in the coronary arteries. ACS includes ST-elevation myocardial infarction (STEMI), non-STEMI, and unstable angina. A STEMI heart attack is the complete blockage of the coronary artery. Non-STEMI heart attack is the partial blockage of the artery that leads to a severe reduction of the blood flow.
According to a senior analyst at Technavio for cardiovascular and metabolic disorders, “STEMI is associated with a high risk of mortality and disability. According to a research, women are at a higher risk of ACS when compared with men. Thus, the mortality rate because of ACS is higher among women. A 12-lead electrocardiogram is usually used to diagnose ACS.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Acute coronary syndrome segmentation
This market research report segments the acute coronary syndrome market based on therapies employed (monotherapy and combination therapy), RoA (oral, IV, subcutaneous, and unknown), therapeutic modalities (small molecules, biological, small molecule + biological, and unknown), targets for drugs under development (apolipoprotein A I, proprotein convertase subtilisin/ kexin type 9 (PCSK 9), ATP binding cassette transporter A1 (ABCA 1), cholesteryl ester transfer protein (CETP), mammalian target of rapamycin (mTOR), MMP 9, P38 mitogen-activated protein (MAP) kinase, platelet 1b receptor, platelet receptors GPIIb - IIIa and ADP, P2Y12 adenosine diphosphate, unknown, and vascular injury site), and recruitment status (recruiting, completed, not yet recruiting and unknown).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 13 molecules are for monotherapy. Whereas, one molecule in the pipeline is being developed for combination therapy.
Around 43% of the molecules that are in the current pipeline are being developed for administration through IV. It was followed by molecules in the oral, subcutaneous, and unknown segments respectively.
|
Save big with Technavio this May! Find out what companies are venturing in to beat the heat this summer! Technavio indulges you with a massive 20% OFF on all non-alcoholic beverages reports for the entire month. OR Technavio honors the achievements and efforts of Motherhood this Mother's Day by offering a whopping 30% OFF on all cosmetics and toiletry reports. Offer valid from 7th May for a limited period. |
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
